Disease Burden and Changing Trends of Kidney Cancer between 1990 and 2021: A Comparative Analysis of China and the World

Zhongli Qiao, Lin Chen, Shenyu Zhang, Jialin Wang, Runze Chen, Jun XiongResearch Square 2024 · DOI

TL;DR

While kidney cancer rates are rising globally, China has experienced a surge in incidence and prevalence nearly three times faster than the global average over the last three decades. However, there is a silver lining: thanks to advancements in healthcare, China’s survival proxy (1-MIR) has climbed from 0.36 to 0.62, surpassing the global average since 2010.

What Problem Does This Paper Address?

Kidney cancer is a significant public health challenge, yet its trajectory varies wildly across the globe. While some Western nations are seeing a plateau or decline in mortality, developing nations—particularly China—are facing a rapidly growing burden.

The authors identify a critical gap in the literature: a lack of comparative, longitudinal analysis that tracks how kidney cancer trends in China diverge from global patterns. By understanding these shifts in incidence, mortality, and survival across different age groups and genders, policymakers can better tailor prevention and intervention strategies.

Methods

The researchers conducted a retrospective analysis using data from the Global Burden of Disease (GBD) 2021 study. They focused on four primary metrics:

  • Incidence and Prevalence: How many new and existing cases exist.
  • Mortality: Death rates.
  • DALYs (Disability-Adjusted Life Years): A measure of overall disease burden, representing years of life lost due to ill-health, disability, or early death.

To ensure fair comparisons across different time periods and regions, all rates were age-standardized. The study utilized two key statistical tools:

  1. Joinpoint Regression Model: Used to calculate the Average Annual Percent Change (AAPC), which identifies the magnitude and direction of trends over time.
  2. 1-MIR (1 minus Mortality-to-Incidence Ratio): This serves as a surrogate indicator for the 5-year relative survival rate and the effectiveness of cancer control programs.

Datasets

The study relies exclusively on the Global Burden of Disease (GBD) 2021 database, accessed via the Global Health Data Exchange (GHDx). This dataset covers 459 diseases and injuries across 204 countries and territories, providing a robust foundation for comparative epidemiological research.

Key Insights and Ideas

  • The "China Speed" of Cancer Growth: Although China's absolute age-standardized incidence rate (3.319 per 100,000) remains lower than the global average (4.524 per 100,000), the rate of increase in China is staggering. The AAPC for incidence in China was 1.98% compared to just 0.49% globally.
  • The Gender Gap is Widening: Kidney cancer is disproportionately a "male" disease. In China, the incidence rate for men increased by 2.33% annually, significantly outpacing the 1.12% increase in women. This is particularly pronounced in middle-aged men (40–54 years old).
  • Survival Success Story: One of the most striking findings is the reversal in survival trends. In 1990, China’s 1-MIR (0.36) was well below the global average (0.49). By 2021, China’s 1-MIR reached 0.62, overtaking the global average of 0.58. This suggests that China's healthcare advancements and early detection efforts are paying off.
  • The "Overdiagnosis" Factor: The authors suggest that the sharp rise in incidence might be partially attributed to "overdiagnosis"—the increased detection of small, asymptomatic renal masses due to the widespread adoption of advanced imaging technologies like CT and ultrasound.

Key Results

  • Prevalence Surge: China’s age-standardized prevalence rate jumped from 7.191 in 1990 to 17.754 per 100,000 in 2021.
  • AAPC Disparity: The AAPC for prevalence in China was 2.94%, more than triple the global average of 0.89%.
  • Mortality Trends: While global age-standardized mortality is slightly decreasing (AAPC -0.13%), China’s is still slightly increasing (AAPC 0.18%), driven largely by the rising death rates in men.
  • DALYs: Interestingly, the age-standardized DALYs rate decreased in both China (-0.28%) and globally (-0.37%), suggesting that while more people are getting the disease, the "burden" per case is being mitigated by better management.

Limitations and Future Work

The authors acknowledge several limitations:

  • Data Source Constraints: As a secondary analysis of GBD data, the study is subject to the inherent limitations and potential estimation biases of the original dataset.
  • The Overdiagnosis Paradox: It remains difficult to distinguish between a true increase in disease "biological" incidence and an increase driven by better screening.
  • Risk Factor Complexity: While smoking, BMI, and hypertension are cited as major drivers, the study does not fully untangle how these factors interact with specific genetic or environmental backgrounds in the Chinese population.

Future Work: The researchers call for more granular studies on risk factor exposure and the development of gender-specific prevention strategies, particularly targeting middle-aged men who currently face the highest burden.

Summary updated

Abstract

<title>Abstract</title> Background Kidney cancer, a prevalent malignant tumor in the urinary system, poses a significant disease burden and remains a crucial public health concern. Methods Utilizing GBD2021 data, our study examined the standardized incidence, mortality, prevalence, and DALYs rate of renal cancer. We calculated the (1-MIR) value to assess treatment outcomes and survival rates, employed a joinpoint regression model to determine the AAPC, and conducted comparative and longitudinal analyses between China and global trends. Through the joinpoint regression model, we calculated the AAPC and conducted a comprehensive analysis of the disease burden of kidney cancer, evaluating its current status and changing trends. Results From 1990 to 2021, the age-standardized incidence rate, age-standardized mortality rate, age-standardized prevalence rate, and age-standardized DALYs rate of kidney cancer in China were lower than those in the world as a whole. However, the growth rate in China was significantly faster than the global average. The age-standardized incidence rate and prevalence rate of kidney cancer in males showed a greater increase compared to females, both in China and globally. Additionally, the age-standardized rate of kidney cancer in males was notably higher than in females, particularly among middle-aged males. The (1-MIR) of renal cancer increased from 0.36 to 0.62 in China and from 0.49 to 0.58 globally. Overall, the treatment effect of renal cancer has shown some successful outcomes. Conclusions From 1990 to 2021, there was a noticeable increase in the global incidence of kidney cancer. Specifically, the standardized incidence and prevalence of kidney cancer in the Chinese population saw a more rapid rise compared to the global trend. Additionally, the disease burden of kidney cancer remained significantly higher in males than in females.
BibTeX
@inproceedings{qiao2024disease,
  author = {Zhongli Qiao and Lin Chen and Shenyu Zhang and Jialin Wang and Runze Chen and Jun Xiong},
  title = {{Disease Burden and Changing Trends of Kidney Cancer between 1990 and 2021: A Comparative Analysis of China and the World}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4606810/v1},
}
Figure